homepage

Display press release or media coverage on homepage

Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound For Excessive Daytime Sleepiness

Read More

Serial NC team eyes another deal with latest biotech

Serial NC team eyes another deal with latest biotech

Read More

Aerial Biopharma Wins Triangle Business Journal’s Best Early-Stage Development Company

Aerial Biopharma Wins Triangle Business Journal’s Best Early-Stage Development Company

Read More

Chattanooga Investment Firm, After Selling 2 Prior Businesses, Develops New Sleep Treatment

Chattagnooga Investment Firm, After Selling 2 Prior Businesses, Develops New Sleep Treatment

Read More

ADX-NO5 Results Presented at SLEEP 2013 Meeting

BALTIMORE, MD- June 3, 2013 – Results from Aerial BioPharma’s Phase 2a clinical trial evaluating the efficacy and safety of ADX-N05 for the treatment of excessive daytime sleepiness in adult subjects with narcolepsy will be presented at the SLEEP 2013 meeting in Baltimore, MD this week.  A total of 33 patients were randomized and completed both N05 and placebo periods in this double-blind, placebo-controlled, multicenter, crossover study.  The average sleep latency across the 4 trials on the Maintenance of Wakefulness Test (MWT), an objective measure of the severity of excessive...

Read More

NC development team nabs $5M angel tranche for its latest biotech play

February 20, 2013 | By John Carroll Just about every biotech investor out there has been looking for just the right recipe of money, time and multiples to justify the high risk involved in betting on drug development. The decade-long cycle in search of a 10x or better return is in distinct disfavor now, with investors looking for tighter timelines and better odds in exchange for smaller but more predictable payoffs. And a tightly knit team of developers in North Carolina has been putting their own twist on the game, with some solid returns from a series of new, if somewhat low-profile,...

Read More